ERBB2 and gastric cancer: Therefore, early introduction to combined treatment of trastuzumab and immunotherapy, such as pembrolizumab, may show benefit in the objective response rate of HER2‐amplified GC, as was recently demonstrated in the KEYNOTE‐811 trial.35